INTERCEPT is not approved for sale in the US and certain other countries.

INTERCEPT Blood System for Plasma

Parasites

The INTERCEPT Blood System for plasma has been shown to inactivate contaminating parasites. Various in vitro studies have demonstrated inhibition of parasite replication following photochemical treatment. The results of these studies are summarized in Table 3.

Table 3: Inactivation Claims - Parasites

Parasites Tested Using the INTERCEPT Blood System for Plasma	Extent of Inactivation* (log₁₀ reduction)
Plasmodium falciparum** (malaria)	≥6.9
Trypanosoma cruzi (Chagas’ disease)	>5.0
Babesia microti (babesiosis)	>5.3

* “>” refers to inactivation below the limit of detection of the assay
“≥” refers to inactivation at or below the limit of detection of the assay
** intracellular

Plasma Technical Data Sheet Page 5 of 7

© 2013 Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.

Legal Info | Privacy Policy